Cannabis sativa L. (cannabis) extracts, vapor produced by the Volcano
® vaporizer and smoke made from burning cannabis joints were analyzed by GC-flame ionization detecter (FID), GC-MS and HPLC. Three different medicinal cannabis varieties were investigated Bedrocan
®, Bedrobinol
® and Bediol
®. Cannabinoids plus other components such as terpenoids and pyrolytic by-products were identified and quantified in all samples. Cannabis vapor and smoke was tested for cannabinoid receptor 1 (CB1) binding activity and compared to pure Δ
9-tetrahydrocannabinol (Δ
9-THC). The top five major compounds in Bedrocan
® extracts were Δ
9-THC, cannabigerol (CBG), terpinolene, myrcene, and
cis-ocimene in Bedrobinol
® Δ
9-THC, myrcene, CBG, cannabichromene (CBC), and camphene in Bediol
® cannabidiol (CBD), Δ
9-THC, myrcene, CBC, and CBG. The major components in Bedrocan
® vapor (>1.0 mg/g) were Δ
9-THC, terpinolene, myrcene, CBG,
cis-ocimene and CBD in Bedrobinol
® Δ
9-THC, myrcene and CBD in Bediol
® CBD, Δ
9-THC, myrcene, CBC and terpinolene. The major components in Bedrocan
® smoke (>1.0 mg/g) were Δ
9-THC, cannabinol (CBN), terpinolene, CBG, myrcene and
cis-ocimene in Bedrobinol
® Δ
9-THC, CBN and myrcene in Bediol
® CBD, Δ
9-THC, CBN, myrcene, CBC and terpinolene. There was no statistically significant difference between CB1 binding of pure Δ
9-THC compared to cannabis smoke and vapor at an equivalent concentration of Δ
9-THC.
View full abstract